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KEY POINTS 
1. Both mature KIR+ and immature KIR- NK cells exert anti-leukemic activity towards pediatric 
BCP-ALL in vivo.  
2. In vivo treatment with low-dose 5-Aza-cytidine enhances immature and mature NK cell 
counts and promotes anti-tumor response. 
 
ABBREVIATIONS 
BCP-ALL acute B cell precursor leukemia 
DNMT  DNA methyltransferase  
GvL  Graft versus leukemia 
huNSG humanized NOD.Cg-Prkdcscid IL2rgtmWjl/Sz mice 
HSC  hematopoietic stem cells 
HSCT  hematopoietic stem cell transplantation 
KIR / KIRL killer immunoglobulin-like receptor / KIR ligand  
NKAES NK cell activation and expansion system 
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ABSTRACT 
 
Therapeutic natural killer (NK) cell-mediated alloreactivity towards acute myeloid leukemia 
(AML) has largely been attributed to mismatches between killer immunoglobulin-like 
receptors (KIRs) on NK cells and their ligands, HLA class I molecules, on target cells. While 
adult acute B cell precursor leukemia (BCP-ALL) appears to be resistant to NK cell-mediated 
lysis, recent data indicate that pediatric BCP-ALL might yet be a target of NK cells. We here 
demonstrate in a donor-patient-specific NOD.Cg-Prkdcscid IL2rgtmWjl/Sz (NSG) 
xenotransplantation model that NK cells mediate considerable alloreactivity towards pediatric 
BCP-ALL in vivo. Notably, not only adoptively transferred mature, KIR+ NK cells but also 
immature, KIR- NK cells arising early post transplantation in humanized NSG mice (huNSG) 
exerted substantial anti-leukemic activity. Low-dose and long-term treatment of huNSG mice 
with the DNA-demethylating agent 5-Aza-cytidine distinctly enhanced the anti-tumor 
response, interestingly without inducing common inhibitory KIR expression but rather by 
promoting the differentiation of various NK cell precursor subsets. Collectively, these data 
indicate that the future design of innovative therapy protocols should consider further 
exploitation of NK cell-mediated immune-responses for poor prognosis pediatric BCP-ALL 
patients. 
 
 
 
 
 
 
 
 
For personal use only.on December 9, 2014. by guest  www.bloodjournal.orgFrom 
Kübler et al. NK cells control pediatric BCP-ALL in vivo. 
 4 
INTRODUCTION 
 
Natural killer (NK) cells belong to innate lymphoid immune cells that contribute to anti-tumor 
responses without prior sensitization. One important receptor family that controls NK cell 
activity constitutes the HLA class I-restricted killer immunoglobulin-like receptor (KIR) family 
that comprises both inhibitory and activating family members which recognize allotypic 
variants of HLA class I alleles as KIR ligands (KIRL). In the setting of haplo-identical 
hematopoetic stem cell transplantation (HSCT), NK cells maturing in a HLA-disparate 
recipient will be shaped in the predominantly donor-type-like hematopoietic niche and will 
thus be donor-tolerant and recipient-“alloreactive”, at least during the first months after 
reconstitution.1-3 In this regard, the beneficial effects of promoting a certain degree of donor-
recipient HLA-disparity was initially described by the Perugia group that provided evidence 
that allogeneic HSCTs performed with grafts from KIR-KIRL mismatched donors promoted 
NK cell alloreactivity and enhanced survival rates in adult patients with acute myeloid 
leukemia (AML) but not with B cell precursor leukemia (BCP-ALL).4,5 As a result of this 
apparent resistance of adult BCP-ALL to NK cell-mediated lysis, the usefulness of NK cell 
immune-responses in treating BCP-ALL has been questioned and research in this field has 
largely been neglected. However, recent data indicate that the disease entity of pediatric 
BCP-ALL might yet be a target of “alloreactive” NK cells.1,2,6-8 Considering the various 
potential facets of NK cell immune therapy such as adoptive transfer of mature NK cells, co-
transfer of mature NK cells during graft manipulation, emergence of immature NK cells early 
post transplantation and the currently existing limited number of clinical studies in BCP-ALL-
bearing children, we sought to define conditions under which NK cell-mediated alloreactivity 
towards pediatric BCP-ALL could be fully exploited. 
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MATERIALS AND METHODS  
 
Mice 
NOD.Cg-Prkdcscid IL2rgtmWjl/Sz (NSG) mice were purchased at “The Jackson Laboratory” and 
maintained under specified pathogen-free conditions in the research animal facility of the 
University of Tuebingen, Germany. All experimental animal procedures were conducted 
according to German federal and state regulations. 
 
Induction of leukemia in NSG mice 
Patient-specific leukemia was induced in NSG mice as described before.9 The study was 
approved by the local ethics committee and written informed consent was obtained from the 
parents, in accordance with the Declaration of Helsinki. Upon engraftment, mice were 
sacrificed and bone marrow (BM) or spleen specimens of leukemia-bearing mice were stored 
at -80° C for de novo generation of patient-specific leukemia at later time points.   
 
NK cell activation and expansion system (NKAES) 
Peripheral blood mononuclear cells (PBMCs) from HLA-typed donors (sequence-based 
typing with 4-digit resolution) (Supplemental Table S1) were used with informed consent to 
expand NK cells in a medium containing 100 IU/ml IL2 (Novartis, Switzerland) using 
irradiated, membrane bound (mb)IL15-41BBL expressing K562 cells generously provided by 
D. Campana (University Children's Hospital, Singapore) at a ratio of 1:1.5.10 To expand NK 
cells in a GMP-guided fashion, pooled human fresh frozen plasma instead of FCS was used. 
Expanded cells were harvested after 14 days and frozen in the presence of 10% DMSO at    
-80° C. Prior to experiments, NKAES cells were thawed and cultured overnight in the 
presence of 100 IU/ml IL2 for in vitro cytotoxicity assays or adoptive transfer experiments 
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and 200 IU/ml IL2 for functional NK cell response staining or alloreactive NK cell subset 
analysis.  
 
Adoptive NK cell transfer  
Donor-patient-pairs were selected that provided a mismatch or match in their KIR-KIRL 
repertoire (Table 1; Supplemental Tables S1 and S2). 1 x 106 blasts were intravenously 
injected into unirradiated NSG mice on d0, followed by intravenous injection of 10 x 106 
NKAES cells at the indicated time points. To monitor engraftment of leukemia, PBMCs of 
NSG mice were subjected to flow-cytometric analysis using formerly defined patient-specific 
leukemia surface markers.  
 
Humanization of NSG mice 
Humanization of NSG mice was performed as described before.11 Following approval by the 
local ethics committee, parents donated < 5% of the hematopoietic stem cells (HSCs) for 
humanization of NSG mice. In selected experiments, HLA-typed HSCs were purchased from 
Key Biologics (Memphis, TN, USA). To induce maturation of NK cells, huNSG mice were 
treated at 12 weeks post transplantation with a complex of IL15/IL15Rα.12 In addition, huNSG 
mice were injected once on d15 post initiation of IL15 stimulation by intraperitoneal 
administration of 100 µg poly I:C (Sigma Aldrich, Taufkirchen, Germany).13 
 
Determination of in vivo cytotoxicity  
Individual donor-patient-pairs were selected that provided a mismatch or a match with 
respect to their KIR-KIRL repertoire. Mice were transplanted with HSCs of the respective 
donor and activated as described above at 12-20 weeks post transplantation. To study NK 
cell-mediated cytotoxicity, 3 x 106 blasts were intravenously injected into huNSG and the 
extent of blasts was determined at 20hrs post injection in the BM using polychromatic (8-11) 
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color flow-cytometry. In some experiments, a mixture of 3 x 106 NSG-derived blasts (total 6 x 
106 blasts) of two patients with varying KIR-KIRL repertoires were injected into huNSG mice 
and leukemia was quantified using the hierarchical gating strategy depicted in Figure S5A. In 
all experiments, the frequencies of patient-specific vital blasts were normalized to vital 
murine CD45+ cells.  
 
In vivo treatment of huNSG mice with 5-Aza-cytidine 
On d39 post transplantation, huNSG mice were randomly assigned to treatment or control 
group and therapy with 5-Aza-cytidine (0.025mg/mouse/dose intraperitoneally, twice a week 
for a total of 4 weeks) or PBS as control was initiated. 4 weeks later, 3 x 106 blasts were 
intravenously injected into 5-Aza-cytidine or sham-treated animals. 20hrs later, mice were 
sacrificed and subjected to analysis of NK cell phenotype and for quantification of leukemic 
burden.  
 
Functional NK cell response staining 
Sorted KIR+ and KIR- (for the respective sorting KIR mAb cocktail refer to Suppl. Data) 
NKAES subsets were co-cultured for 6hrs with NALM-16 or K562 cells (E:T ratio of 1:2) in 
the presence of CD107a-APC (H4A3) (BD Pharmingen). Subsequently, NK cells were 
stained with the indicated surface antibodies, permeabilized and co-stained with the 
respective intracellular antibodies (Perforin-PB (dG9) and TNF-bv605 (MAb11)) (Biolegend). 
For determination of IFN-γ, unsorted NKAES cells were co-cultured with the respective target 
cells, were subsequently stained with surface antibodies (including the above mentioned 
anti-KIR antibody cocktail), and finally stained with IFN-γ-BUV395 (B27) antibody (BD 
Horizon). Percentages of the respective NK cell subpopulation were then normalized to the 
baseline levels of NKAES cells cultured in control medium only. The specificity of the 
intracellular perforin staining was additionally verified by determining the perforin 
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concentration in the co-culture supernatants using the Diaclone Perforin ELISA KIT (ACTIVE 
BIOSCIENCE, Germany). 
 
Alloreactive NK cell subset analysis 
Unsorted NKAES cells were co-cultured with the respective target cells in the presence of 
CD107a-bv421 (H4A3) and subsequently stained with the following mAbs: KIR3DL1 (DX9, 
BD Pharmingen), KIR2DL2/L3/S2 (GL183, Beckman Coulter), KIR3DL1/S1 (Z27.3.7, 
Beckman Coulter) and KIR2DL1/S1/S4 (HP-3E4, BD Pharmingen). The selective 
combination of anti-KIR mAbs with different or identical fluorochromes hereby allowed the 
discrimination KIR- and non-alloreactive or alloreactive KIR+ NK cell subsets in the context of 
Bw4/C1 target cell recognition. 
 
Statistics  
Statistic advice was obtained from M. Eichner, PhD, Department of Clinical Epidemiology 
and Applied Biometry, University of Tuebingen, Germany, and M. Urschitz, MD, Institute of 
Medical Statistics, University of Mainz, Germany. Mean values and SEM from experiments 
with 2 conditions were analyzed with the Student t test. The effect size Θ was calculated 
using the standardized mean difference between two populations:  Θ  = (μ1-μ2) / σ, where 
μ1 and 2 represent the mean values of the two study groups and σ represents the SEM of 
total study population.  
 
Methods concerning flow-cytometric analyses, determination of in vitro cytotoxicity 
and KIR-Q-PCR are referred to in Supplemental Materials and Methods.  
  
 
 
For personal use only.on December 9, 2014. by guest  www.bloodjournal.orgFrom 
Kübler et al. NK cells control pediatric BCP-ALL in vivo. 
 9 
RESULTS 
 
KIR-KIRL mismatch constellations promote the alloreactivity of cytokine-matured NK 
cells towards pediatric BCP-ALL in vitro and in vivo.  
To characterize the alloreactivity of mature NK cells in various KIR-KIRL repertoire 
constellations, we applied a previously described good manufacturing process (GMP)-guided 
NK cell activation and expansion system (NKAES)10 and generated large numbers of 
cytokine-matured NK cells of donors with defined HLA class I genotypes (Supplemental 
Table S1), KIR repertoires (Supplemental Table S2) and NK cell surface phenotypes 
(Supplemental Figure S1A, B). We then chose a pediatric AML (Kasumi-1) and a BCP-ALL 
cell line (NALM-16) which express important NK cell receptor ligands to a comparable and 
significant extent (Figure S1C) to test whether KIR-KIRL mismatched NK cells can in 
principle target pediatric BCP-ALL. Indeed, KIR-KIRL mismatched NK cells exerted 
alloreactivity not only towards a pediatric AML but also a BCP-ALL cell line (Figure S2A). 
Comparative analysis of in vitro cytotoxicity assays performed with other pediatric BCP-ALL 
cell lines hereby demonstrated that this alloreactivity was clearly dependent on the extent of 
NKG2DL expression (Figure S2B, C). To further describe the relevance of KIR-KIRL 
interactions that might provide functional NK cell competence in addition to the immanent 
NKG2D-restricted activation, we performed cytotoxicity assays with donors that exhibited 
either a KIR-KIRL mismatch or a match towards two given BCP-ALL specimen (P3B relapse, 
P31G) (Table 1). In vitro cytotoxicity assays demonstrated that alloreactivity to BCP-ALL was 
better for those NK cells that were not subject to inhibition by self-HLA molecules (Figure 
1A). In addition, injection of NKAES cells from a KIR-KIRL mismatched donor into P3B-
engrafted NSG mice resulted in a higher reduction of tumor burden than transfer of the 
respective control NK cells (Figure 1B, C).  
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The KIR+ NK cell subset of KIR-KIRL mismatched donors exerts higher cytotoxicity 
towards BCP-ALL than the corresponding KIR- subset.  
To further characterize the functional repertoire of NKAES cells with regard to potential KIR-
KIRL mismatch constellations, we sorted KIR+ and KIR- NK cell subsets. The KIR+ NK cell 
subset of KIR-KIRL mismatched donors uniformly demonstrated higher levels of cytotoxicity 
when compared to the respective KIR- controls (Figure 2A), a phenomenon that became 
even more evident upon normalization (Figure 2B). In contrast, the KIR+ NK cells of matched 
donors invariably exhibited impaired cytotoxicity, indicating that functionality might have been 
compromised in response to inhibitory KIR-KIRL interactions. Cytotoxicity assays performed 
in the presence of the common inhibitory KIR2DL1 and 2DL2/3 blocking mAb IPH210214 
revealed that the lytic activity of KIR+ NK cells of KIR-KIRL matched, HLA-C1 homozygous 
donors must have been controlled by inhibitory interactions of KIR2DL2 and 2DL3 receptors 
with their respective HLA-C1 group ligands expressed on NALM-16 cells (Figure 2C). In 
contrast, the KIR2DL2 and 2DL3+ NK cell subset of our KIR-KIRL mismatched, HLA-C2 
homozygous donors did not respond to inhibitory KIR blockade.  
 
The alloreactive KIR+ NK cell subset of KIR-KIRL mismatched donors exhibits a 
superior ability for degranulation in response to pediatric BCP-ALL. 
Facing this high cytotoxic activity of KIR+ NK cells towards KIRL-negative BCP-ALL target 
cells, one would expect significant differences in assays quantifying the ability for cytokine 
secretion or degranulation. Indeed, KIR-KIRL mismatch constellations boosted to some 
extent the ability of KIR+ NK cells for both (Figure 3 and S3), however, these data did not 
reach statistical significance. To further dissect the extent of anti-tumor responses of KIR+ NK 
cells, we therefore analyzed the ability for degranulation in the alloreactive and non-
alloreactive NK cell subsets (Figure 4A, for the respective NK cell phenotype see Figure 
S1B). Alloreactive KIR+ NK cells from mismatched donors revealed a superior capacity for 
degranulation in comparison to alloreactive KIR+ NK cells from matched donors (Figure 4B-
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D). This was first of all true for the KIR+NKG2A- NK cell subset but to some extent also for 
the cytokine-activated and thus expanded KIR+NKG2A+ subset. Interestingly, the KIR-KIRL 
mismatched donor SNK14B had very little alloreactive KIR+ NK cells (Figure S4) explaining 
the comparatively poor killing ability depicted in Figure 2A. In summary, we at this point 
conclude that cytokine-matured NK cells of KIR-KIRL mismatched donors can exert a 
substantial cytotoxicity towards pediatric BCP-ALL cells which is above all conferred by vivid 
degranulation of alloreactive KIR+ NK cells.  
 
Immature, KIR- NK cells exert alloreactivity towards pediatric BCP-ALL.  
Since humans first reconstitute a large pool of immature KIR- NK cells early post 
transplantation2,15,16, we next asked whether these NK cells might also exert effector 
functions against pediatric BCP-ALL. As KIR acquisition in NSG mice transplanted with 
human hematopoietic stem cells (HSC) (huNSG) will occur only in a minor fraction of 
huNSG-derived NK cells (André MC & Münz C, own unpublished data), we chose this NSG 
xenotransplantation model as a surrogate model for the generation of “pseudo-mature lytic 
NK cells”17 arising in the early post transplantation period in humans (Figure 5A). The 
injection of a primary BCP-ALL specimen (P23T) into huNSG mice pre-stimulated with 
IL15/IL15Rα and poly I:C resulted in a substantial reduction of P23T tumor burden compared 
to control mice (Figure 5B). Since these results suggested that huNSG-derived NK cells may 
in principle be functionally active, we next injected a pooled sample of equal numbers of two 
primary BCP-ALL samples (P3B and P23T) with different KIRL repertoires into huNSG mice 
(Figure 5C). Applying the sequential gating strategy depicted in Figure S5A and verifying that 
the huNSG-derived NK cells were indeed to a large extent negative for common KIRs (Figure 
5D), we found that the KIR-KIRL mismatched sample P3B was significantly better killed than 
the matched sample P23T (Figure 5E). Of note, we deliberately euthanized huNSG mice 
20hrs post injection of leukemia to exclude for T cell-mediated responses as a major cause 
of leukemia reduction. As the alloreactivity towards P3B and P23T was reversible in 
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experiments performed with a different HSC donor (Figure S5B), we conclude that the 
alloreactivity towards P3B depicted in Figure 5E was not a result of a P3B-intrinsic slower 
growth rate. Given that HLA class I, ICAM-1, NKG2D and DNAM-1 ligands (Figure S1C) 
were expressed to a comparable extent by P3B and P23T, we assume that either KIR-KIRL 
interactions other than the one analyzed by us (KIR2DL1/S1/S4, KIR2DL2/S2/L3 and 3DL1) 
or modest differences, i.e. in the expression of NKG2DL, must have contributed to this 
phenomenon.  
 
“Bridging” therapy with 5-Aza-cytidine supports NK cell alloreactivity towards 
pediatric BCP-ALL in the early post transplantation period.  
To elaborate the full potential of the immature NK cell pool arising early post-transplantation, 
we recapitulated existing in vitro data indicating that 5-Aza-cytidine modulates NK cell 
function by inducing KIR promoter activity18 and expression19 in our xenotransplantation 
model in the context of pediatric BCP-ALL disease. As the therapeutic efficacy of DNA 
methyltransferase (DNMT) inhibitors may reach from the induction of DNA-demethylating 
effects at low doses to the induction of direct cytotoxic effects at higher doses, we decided to 
apply a low-dose treatment regimen for an extended period to potentially enable long-term 
epigenetic modulation of NK cells (Figure 6A). This treatment regimen resulted in a 
statistically not significant reduction of both human and murine CD45+ cells, reflecting to 
some extent a drug-induced BM cytotoxicity (Figure 6B, C). Interestingly, contrary to 
previously published in vitro data reporting a 5-Aza-cytidine induced functional inhibition of 
mature NK cells20, we observed a clearly reduced BCP-ALL burden in 5-Aza-cytidine-treated 
huNSG mice (Figure 6D, F). Of note, we had stopped 5-Aza-cytidine therapy three days 
before the injection of leukemia and the half-life of the drug is described to be less than 
4hrs.21 Together with our data obtained in non-humanized controls (Figure 6E), we can 
therefore largely exclude a drug-induced, direct cytotoxic effect that might have reduced the 
tumor load.  
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Low-dose and long-term exposure to 5-Aza-cytidine promotes NK cell ontogeny.  
NK cell receptor analysis of huNSG mice revealed that 5-Aza-cytidine did not significantly 
modulate the expression of selected NK cell receptors (KIRs, NKG2A, NKp44 and NKG2D) 
at the low doses applied (Figure 7A, B). However, the analysis of NK cell subsets 
interestingly showed that 5-Aza-cytidine-treated huNSG mice had clearly higher numbers of 
both immature (CD34+CD117+ and CD34-CD117lowCD94-) NK cell precursors and mature 
(CD34-CD117-CD94+NKp46+ and CD34-CD117-CD94-NKp46+) NK cell subsets22 (Figure 7C), 
indicating that 5-Aza-cytidine might have facilitated NK cell ontogeny itself.  
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DISCUSSION 
 
Given the disparity of adult and pediatric acute lymphoid leukemia, we here sought to 
investigate NK cell-based immune responses to the tumor entity pediatric BCP-ALL. Our 
data reveal that not only mature KIR+ but interestingly also immature KIR- NK cells control 
pediatric BCP-ALL in vivo and indicate that future protocols should consider further 
exploitation of NK cell-mediated immune-responses for poor prognosis pediatric BCP-ALL 
patients. 
The difference in the susceptibility of adult and childhood BCP-ALL to NK cell-mediated lysis 
has been mainly ascribed to differing expression of cell adhesion molecules of the β1 and β2 
integrin and the Ig superfamily, respectively, that essentially results in a reduced NK cell-
target conjugate formation and activation in the case of adult BCP-ALL.4,23 In addition, the 
surface density of HLA class I ligands is greater and the expression of ligands to major 
activating NK cell receptors such as NKG2D is lower in pediatric BCP-ALL as compared to 
AML.24 In line with this, our group earlier demonstrated that the in vitro cytolytic activity of NK 
cells against BCP-ALL in part correlated with the extent of MHC expression on the respective 
specimen.6,7  
Accounting for our previous work that demonstrated that the injection of patient-specific 
leukemia into NSG mice results in the constitution of a model that reflects individual 
leukemogenecity9, we analyzed the leukemic burden in BCP-ALL-bearing mice upon 
adoptive NK cell transfer and demonstrated that KIR-KIRL mismatched NK cells targeted but 
did not eliminate pediatric BCP-ALL. Mechanistically, the interaction of NK cells with BCP-
ALL was accompanied by a heightened functionality of alloreactive KIR+ NK cells of KIR-
KIRL mismatched donors, particularly in terms of their ability for degranulation. As the 
presence of the inhibitory KIR blocking mAb IPH2102 distinctly enhanced the cytotoxicity of 
matched KIR+ NK cells, we conclude that the KIR-KIRL axis indeed contributes to the control 
of NK cell alloreactivity and hypothesize that this antibody might provide clinically significant 
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effects in selected young BCP-ALL patients. The absence of effectiveness of KIR blockade in 
our KIR-KIRL mismatched C2/C2 donors is difficult to explain as inhibitory signaling alone 
should be functional even in KIR2DL2/L3+ NK cells of these donors. However, the 
KIR2DL2/L3+ NK cell subset that lacked the co-expression of other inhibitory KIRs was 
comparatively large in our donors and displayed, despite the presence of NKG2A, a low 
functional ability in terms of response to K562 (data not shown). Thus, we at this point 
assume that these two findings together might explain the decreased responsiveness to IPH 
in our C2/C2 mismatched donors.  
Irrespective of the individual KIR-KIRL constellation, the KIR- NK cell subset interestingly 
enough displayed substantial functionality. In line with the previously published observation 
that the attenuated function of KIR- NK cells can be overcome by exposure to cytokines25, we 
attribute this observation to the cytokine-rich expansion protocol. 
The so far published data on adoptive NK cell transfer in children is restricted to feasibility 
studies performed mostly in AML patients.26 Our group recently demonstrated that the 
infusion of IL15-stimulated CD3-/CD19--depleted HSC grafts (containing high numbers of NK 
cells) is safe even in the haplo-identical setting.8 Given that NK cells can persist and expand 
in HLA-mismatched hosts27 and that the transfer of mature NK cells does obviously not 
promote graft-versus-host-disease (GvHD)8,26, the data depicted here support the concept 
that the adoptive transfer of KIR+ NK cells of KIR-KIRL mismatched donors might indeed play 
a role in the treatment of relapsing BCP-ALL disease, not alone but as an adjunct to haplo-
identical HSCT.  
To date, two clinical studies evaluated the feasibility of KIR-KIRL mismatched haplo-identical 
HSCTs in children with BCP-ALL. Our group demonstrated that the graft-versus-leukemia 
(GvL) effect best correlated with the number of KIR-KIRL mismatches.1 The second study 
was performed by the Moretta group with the aim of better defining the specificity and clonal 
distribution of “alloreactive” NK cells.2 Collectively, these two preliminary studies show that 
the incorporation of theoretical assumptions on KIR-KIRL interactions in haplo-identical 
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HSCTs of children with BCP-ALL is feasible, that such a mode of donor selection does not 
heighten the risk of GvHD and that the analysis of receptor-ligand constellations may have 
prognostic implications.  
We here systematically demonstrate in huNSG mice that emerging KIR- NK cells exert a 
considerable cytotoxicity towards BCP-ALL, thus extending earlier data that a substantial 
number of phenotypically healthy appearing NK cells exist in mice and men that obviously 
lack the expression of any inhibitory receptor for “self”-HLA class I28,29 but nevertheless 
display a certain degree of functionality. In line with previously published data that 
“unlicensed” NK cells may exert a profound immune response in the context of murine 
cytomegalovirus infection30, our data indicate that the anti-tumor properties of immature KIR- 
NK cells are substantial and might just as well have been previously underestimated. As the 
KIR expression in huNSG mice was despite the administration of IL15/IL15Rα complex 
negligible, we at this point do not ascribe the occurring NK cell activation to the lack of KIR-
KIRL-mediated inhibition but rather assume that receptor-ligand interactions other than the 
one analyzed by us must have contributed to this phenomenon.  
Using a humanized xenotransplantation model to analyze GvL potency after haplo-identical 
HSCT is undoubtedly technically challenging and has to our knowledge so far not been 
attempted. The application of minimal residual disease (MRD) analysis based on multi (8-11) 
parameter flow-cytometry enabled the distinction of immunophenotypic features of one (or 
two) patient-specific malignantly transformed B cell specimen from early-arising donor-type 
like B cell-lineage precursors. This approach has allowed us to characterize GvL effects in a 
dynamic and largely functional hematopoietic system that incorporates complex effector-
target cell interactions in the presence of “human-like” bystander cells and supportive 
cytokines.  
As recent data indicate that DNA demethylating agents may not only affect the growth of 
malignant cells but might also modulate inhibitory KIR expression on NK cells, we tested 5-
Aza-cytidine in our huNSG model. Interestingly, we observed a significantly reduced BCP-
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ALL burden in huNSG mice that could not be solely attributed to drug-induced, direct 
cytotoxic effects. This observation is in contrast to previously published in vitro data reporting 
a 5-Aza-cytidine-induced functional inhibition of NK cells20,31, however, careful analysis of 
these data reveals that the knowledge of 5-Aza-cytidine mediated immune-modulation of NK 
cells is basically restricted to studies of mature NK cells of healthy volunteer donors. Analysis 
of BM-residing NK cell subsets in huNSG mice demonstrated that 5-Aza-cytidine-treated 
mice harbored distinctly higher numbers of both immature and mature NK cell subsets. So 
far, it has been speculated that beneficial anti-tumor effects of 5-Aza-cytidine should 
probably be attributed to the induction of HLA class I expression and cancer testis antigens 
on malignant or pre-malignant cell clones.32 In line with this tumor-focussed concept, 5-Aza-
cytidine is used to “bridge” the early post transplantation period in high risk AML and chronic 
myelomonocytic leukemia (CMML) patients.33,34 However, based on our results, we propose 
that 5-Aza-cytidine therapy might induce a re-modelling in developing NK cell precursors that 
– presumably together with an altered DC functionality and a fine-tuned NK cell-promoting 
cytokine milieu35 – leads to increased NK cell numbers and improved functionality.  
In line with the observation that 5-Aza-cytidine may promote differentiation of malignantly 
transformed cells by inducing the re-expression of epigenetically down-regulated PU.136  and 
considering the crucial role that PU.1 plays in the regulation of NK cell differentiation and 
homeostasis37, we assume that the re-expression of PU.1 might have promoted NK cell 
differentiation in our model. In addition, it has been shown for low but not high dose 5-Aza-
cytidine therapy that this may increase the number of cells in the S phase and may thus 
promote cell cycle progression.38 Recalling data that 5-Aza-cytidine therapy does not evoke a 
broad and unspecific passive demethylation of the genome but rather induces a highly 
specific non-random demethylation pattern38, we at this point hypothesize that low dose 5-
Aza-cytidine might have selectively re-shaped factors important for NK cell transcription and 
cell cycle control.  
In summary, we here provide substantial evidence that both KIR+ but also immature KIR- NK 
cells may exert clinically relevant GvL effects towards pediatric BCP-ALL. Our data thus 
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support the rationale for adoptive NK cell transfer of ex vivo activated mature donor-specific 
NK cells that would chaperone the early, NK cell-deficient phase of ideally KIR-KIRL 
mismatched haplo-identical HSCTs in children with relapsing BCP-ALL (Figure 8). The 
application of a low dose 5-Aza-cytidine “bridging” therapy - potentially under supportive 
cytokine administration - might additionally promote NK cell differentiation and functionality 
and would thus constitute an optional treatment strategy for those patients lacking a suitable 
KIR-KIRL mismatched donor.  
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TABLE 1. KIR-KIRL repertoire constellations of donors and patients included in this 
study. Given is the internal de-identification code of the NK cell donors (SNK), stem cell 
donors (SSC), the donor-specific inhibitory KIR repertoire relevant for characterization of the 
alloreactive subset, the KIRL repertoire of the respective BCP-ALL and the identification of 
the educated KIRs that are specific for the missing KIRL in the target cells. Note, that 
KIR2DL1 and KIR2DL2/3 KIR family members recognize HLA-C alleles with Lys80 (C2 
epitope) or Asn80 (C1 epitope) residues, respectively, whereas KIR3DL1 recognizes HLA-A 
and B alleles with a Bw4 supertypic specificity and KIR3DL2 recognizes HLA-A3 and HLA-
A11 alleles. For detailed KIR ligand status and KIR expression data see Supplemental 
Tables S1 and S2. * monoallelic data as the NALM-16 cell line has a near-haploid genome. 
** Note, that in contrast to theoretical assumptions, this donor does not express KIR3DL1 on 
the NK cell surface and does therefore lack a KIR3DL1+ alloreactive NK cell subset. *** Note, 
that the assumption of KIR3DL1 is based on genomic data as huNSG mice lacked inhibitory 
KIR surface expression. **** Genomic expression of KIR2DL2 is absent in this donor. N/A = 
not applicable.  
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Donor KIRL 
Donor education of inhibitory KIRs Educated KIRs specific for the missing KIRL in the target 
Educated Uneducated P3B  
Bw6/Bw6  C1/C1 
P23T 
ABw4/ABw4          
Bw4/Bw4  C2/C1 
P31G 
A3/A3        
Bw4/Bw6  C2/C2 
 
Nalm-16 
Bw4  C1* 
SNK9A  Bw6/Bw6  C1/C1 2DL2, 2DL3 2DL1, 3DL1, 3DL2 / N/A 2DL2, 2DL3 / 
SNK10P Bw6/Bw6  C1/C1 2DL2, 2DL3 2DL1, 3DL1, 3DL2 / N/A 2DL2, 2DL3 / 
SNK21BC A3           Bw6/Bw6  C1/C1 2DL2, 2DL3, 3DL2 2DL1,  3DL1 3DL2 N/A 2DL2, 2DL3 3DL2 
SNK13B  ABw4     Bw4/Bw4  C2/C2 2DL1, ** 2DL2, 2DL3, 3DL2 2DL1, ** N/A / 2DL1 
SNK14B ABw4    Bw4/Bw4  C2/C2 2DL1, 3DL1  2DL2, 2DL3, 3DL2 2DL1, 3DL1 N/A / 2DL1 
SNK15B Bw4/Bw4  C2/C2 2DL1, 3DL1 2DL2, 2DL3, 3DL2 2DL1, 3DL1 N/A / 2DL1 
SNK20B A3          Bw4/Bw4  C2/C2 2DL1, 3DL1, 3DL2 2DL2, 2DL3 2DL1, 3DL1, 3DL2 N/A / 2DL1, 3DL2 
SSC21D Bw4/Bw4  C1/C2 2DL1, 2DL3, 
3DL1***, ****  
3DL2 2DL1, 3DL1 / N/A N/A 
SSC18U ABw4     
Bw4/Bw4  C2/C1 
2DL1, 2DL3, 3DL1, 
*** 
3DL2 2DL1, 3DL1 N/A N/A N/A 
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FIGURE LEGENDS 
 
Figure 1. KIR-KIRL mismatch constellations promote the alloreactivity of cytokine-
matured NK cells towards pediatric BCP-ALL in vitro and in vivo.  
(A) In vitro NK cell alloreactivity towards BCP-ALL is donor-dependent. Shown is the specific 
lysis of KIR-KIRL mismatched or matched donors towards the two chosen BCP-ALL samples 
P3B relapse and P31G (E:T ratio of 10:1). Cytotoxicity towards K562 cells is included as 
positive control. Data represent two independent experiments performed in triplicates. 
Donor/patient specific KIR-KIRL repertoire constellations of the 6 donors SNK9A, SNK10P, 
SNK21BC, SNK13-15B are depicted in the Table 1. (B, C) Donor selection influences the in 
vivo alloreactivity of NKAES cells towards pediatric BCP-ALL. (B) Experimental setup for 
Figure 1C. (C) Adoptively transferred NKAES cells of a KIR-KIRL mismatched donor 
(SNK13B) exert higher in vivo alloreactivity towards P3B than control NKAES cells of a KIR-
KIRL matched donor (SNK10P). Data is representative of one experiment performed with 11 
mice.  
  
Figure 2. The KIR+ NK cell subset of KIR-KIRL mismatched donors exerts higher 
cytotoxicity towards pediatric BCP-ALL than the corresponding KIR- subset.  
(A) Sorted KIR+ and KIR- NK cells of the 7 donors characterized in Table 1 were co-cultured 
with NALM-16 or K562 cells as a control to determine the extent of in vitro cytotoxicity (E:T 
ratio 5:1). (B) Standardization of the data depicted in Figure 2A. Shown is the specific lysis of 
the KIR+ NK cell subset minus the one of the corresponding KIR- NK cell subset. Data 
represent six independent experiments with 7 donors performed in triplicates. (C) 
Interactions of inhibitory KIRs with their cognate ligands determine the extent of NK 
alloreactivity towards pediatric BCP-ALL. Alloreactivity of sorted KIR+ NKAES cells of the 
donors SNK14B, SNK15B, SNK20B (KIR-KIRL mismatch) and SNK10P, SNK21BC (KIR-
KIRL match) against NALM16 was determined by in vitro killing assays (E:T ratio 2:1) in the 
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presence or absence of the common inhibitory KIR-blocking mAb IPH2102. Data represent 
five independent experiments performed in triplicates.  
 
Figure 3. KIR-KIRL mismatch constellations boost the capacity for degranulation and 
cytokine synthesis of KIR+ NK cells towards pediatric BCP-ALL. 
Sorted KIR+ and KIR- NK cells of the donors SNK13-15B, SNK20B (donor group “mismatch”) 
were co-cultured with NALM-16 or K562 cells as a control to determine the functional 
response in terms of degranulation and cytokine synthesis. Pooled data of the intracellular 
staining showing mean ± SEM. Given are the percentages of the respective CD107a+, 
Perforin+, TNF+ and IFN-γ+ NK cell subpopulation normalized to the corresponding baseline 
levels of NKAES cells cultured in control medium only. Note, that due to the genuinely higher 
response the y-axis is differently scaled in K562 experiments. The negative bars indicate the 
decline in perforin levels which accompanies NK cell degranulation. 
 
Figure 4. The alloreactive KIR+ NK cell subset of KIR-KIRL mismatched donors 
exhibits a superior ability for degranulation in response to pediatric BCP-ALL. 
(A-D) NKAES cells of KIR-KIRL mismatched (SNK14B, SNK15B, SNK20B) or matched 
donors (SNK9A, SNK10P, SNK21BC), respectively, were co-cultured with NALM-16 or K562 
cells. Shown is the % CD107a+ CD56+ population in various alloreactive or non-alloreactive 
NK cell subsets. (A) Exemplified gating strategy for the identification of NK cells subsets in 
donor SNK15B. In relation to NALM-16 cells (Bw4/C1), the potentially alloreactive NK cell 
population (upper left quadrant) is here represented by the cells expressing KIR2DL1/S1/S4 
and/or KIR3DS1 (y-axis) but not KIR2DL2/L3/S2 or KIR3DL1 (x-axis). (Note, that the 
combined staining with a KIR3DL1/S1 (Z27.3.7) and a KIR3DL1 (DX9) antibody enables the 
identification of the KIR3DL1-S1+ cell population that belongs to the alloreactive subset). (B, 
C) Representative original histogram data obtained from a KIR-KIRL mismatched (SNK15B) 
and a matched donor (SNK10P). Data in (B) shows CD107a staining in NKAES-only cultures 
(grey, open) and NKAES cells co-cultured with NALM-16 cells (black, open). Data in (C) 
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shows the respective stainings in co-culture experiments with K562 (black, open). The upper 
right pictogram in Figure 4C delineates the respective isotype control (light grey, filled) that 
allows the subsequent marker position and identification of the CD107a+ subset in B and C. 
In each histogram the subtraction result ΔCD107a is given (% CD107a+ cells in NKAES-
tumor co-cultures minus % CD107a+ cells in NKAES-only cultures). Note, that all 
experiments were performed with highly activated NKAES cells that exhibit a significant 
baseline CD107a expression. (D) % CD107a+ CD56+ cells in the indicated NK cells subsets 
of KIR-KIRL mismatched (SNK14B, SNK15B and SNK20B) or matched donors (SNK9A, 
SNK10P and SNK21BC). Shown is the increase in CD107a expression of NALM-16 co-
cultured KIR+ NK cell subsets normalized to the CD107a expression of the corresponding 
KIR- NK cell subset. Symbols: KIR+ alloreactive subset in KIR-KIRL mismatched donors: ●, 
KIR+ alloreactive subset in matched donors: ○, KIR+ non-alloreactive NK cell subset: ■. Data 
represents one experiment performed with the 6 indicated donors. 
 
Figure 5. Immature, KIR- NK cells exert alloreactivity towards pediatric BCP-ALL in 
vivo.  
(A) Experimental setup for humanization of NSG mice. (B) huNSG mice exhibit alloreactivity 
towards pediatric BCP-ALL in vivo. P23T was injected into huNSG or non-humanized control 
mice and leukemic burden was quantified 20hrs later in the BM. Given is the number of vital 
blasts normalized to vital murine CD45+ cells. Figure represents pooled data of two 
independent experiments obtained on a total of 7 huNSG and 3 control mice. (C) 
Experimental setup for Figure 5D and E. (D) KIR Expression (KIR2DL1/S1/S4, 
KIR2DL2/L3/S2, KIR3DL1) on BM-derived CD56+ NK cells of huNSG mice. (E) HuNSG-
derived NK cells from SSC21D exert significantly higher in vivo alloreactivity against P3B 
than towards P23T. Given is the number of BM-residing vital blasts normalized to vital 
murine CD45+. Data is representative of two independent experiments with a total of 4 
huNSG mice.  
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Figure 6. “Bridging” therapy with 5-Aza-cytidine supports NK cell alloreactivity 
towards pediatric BCP-ALL in the early post transplantation period.  
(A) Experimental setup. (B, C) Low-dose and long-term 5-Aza-cytidine treatment does not 
exert statistically relevant BM cytotoxicity. Given is the number of human (B) or murine (C) 
CD45+ cells normalized to total live cells. Data depicted in Figure 6B were obtained in 5-Aza-
cytidine-treated huNSG mice, data depicted in Figure 6C were obtained in 5-Aza-cytidine-
treated non-humanized control mice. (D) Treatment with 5-Aza-cytidine significantly reduces 
BCP-ALL tumor load in huNSG mice. (E) Low-dose 5-Aza-cytidine treatment regimen does 
not exert relevant direct cytotoxic effects on pediatric BCP-ALL. Given is the number of vital 
blasts in the BM normalized to murine CD45+ cells in non-humanized control NSG mice. (F) 
Calculated effect size of in vivo 5-Aza-cytidine treatment on pediatric BCP-ALL burden. “Exp. 
I and II” denote the two different experiments in huNSG mice, “control I and II” denote the 
effect in the respective control groups. Data is representative of two independent 
experiments with a total of 11 huNSG mice and 14 control NSG mice.  
 
Figure 7. Low-dose and long-term exposure to 5-Aza-cytidine promotes NK cell 
ontogeny.  
(A, B) 5-Aza-cytidine does not significantly alter the expression of KIR2DL1/S1/S4, 
KIR2DL2/L3/S2 and KIR3DL1 (A) or other inhibitory or activating NK cell receptors (B) on 
BM-derived NK cells of huNSG mice. (C) 5-Aza-cytidine induces the expression of BM-
residing NK cell precursors. Frequencies of the indicated NK cell subpopulations in the BM of 
5-Aza-cytidine-treated or control huNSG mice (as defined by Freud23): preNK: 
CD34+CD117+, iNK: CD34-CD117lowCD94-, CD94+ mNK cells: CD34-CD117-CD94+NKp46+, 
CD94- mNK cells: CD34-CD117-CD94-NKp46+. Data represent two independent experiments 
with a total of 11 huNSG mice and 14 control NSG mice.  
 
Figure 8. Chaperoning the NK cell-deficient phase of haplo-identical hematopoietic 
stem cell transplantation.  
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Delineation of a hypothetical study design in relapsing pediatric BCP-ALL patients ideally 
exploits NK cell-mediated anti-tumor responses.  
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